2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-dimethylaminoisoindoline-1,3-dione | 253168-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-dimethylaminoisoindoline-1,3-dione
• 英文别名: 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(dimethylamino)isoindole-1,3-dione
• CAS: 253168-93-3
• 化学式: C₂₅H₃₀N₂O₆S
• 分子量: 486.589
• InChiKey: JDYDVMXPJPHYAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl-amine 、 3-dimethylaminophthalic anhydride 以 溶剂黄146 为溶剂， 以The product was obtained as a yellow solid (780 mg, 50% yield)的产率得到
  参考文献：
  名称：

  Substituted phenethylsulfones and method of reducing TNF.alpha. levels

  摘要：

  在苯基的α位被1-氧代异吲哚啉或1,3-二氧代异吲哚啉基取代的苯乙基磺酮可以降低哺乳动物中TNFα的水平。典型的实施例包括2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-氨基异吲哚啉-1,3-二酮和2-[1-(3-环戊氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]异吲哚啉-1,3-二酮。

  公开号：

  US06020358A1

文献信息

• Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
  申请人：Zeldis B. Jerome

  公开号：US20060004054A1

  公开（公告）日：2006-01-05

  Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor α(TNF-α) are used in the invention. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.

  本发明描述了预防和治疗所有形式的动脉粥样硬化的方法和组合物。本发明使用类似沙利度胺（thalidomide）的化合物、其类似物、水解产物、代谢物、衍生物和前体，以及其他能够抑制肿瘤坏死因子α（TNF-α）的化合物。本发明还揭示了使用本发明的化合物对假体设备（如支架）进行涂层，以预防和/或治疗再狭窄。
• Substituted phenethylsulfones and method of reducing TNF.alpha. levels
  申请人：Celgene Corporation

  公开号：US06011050A1

  公开（公告）日：2000-01-04

  Phenethylsulfones substituted in the position .alpha. to the phenyl group with a 1-oxoisoindoline or 1,3-dioxoisoindoline group reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline- 1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline- 1,3-dione.

  α-苯基烷基磺酮在苯基位置上以1-氧代异吲哚啉或1,3-二氧代异吲哚啉基团取代，可降低哺乳动物体内TNF-α水平。典型实施例包括2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-氨基异吲哚啉-1,3-二酮和2-[1-(3-环戊氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]异吲哚啉-1,3-二酮。
• Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
  申请人：CELGENE CORPORATION

  公开号：EP2036553A1

  公开（公告）日：2009-03-18

  Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本文公开了治疗、预防、改变和控制各种类型疼痛的方法。具体方法包括施用选择性细胞因子抑制药物或其药学上可接受的盐、溶液剂、水合物、立体异构体、凝胶体或原药，单独或与第二种活性剂和/或手术、心理或物理疗法联合使用。此外，还公开了适用于本发明方法的药物组合物、单一单位剂型和试剂盒。
• Compositions for treatment of cancers
  申请人：CELGENE CORPORATION

  公开号：EP2258363A1

  公开（公告）日：2010-12-08

  Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本研究公开了治疗、预防和/或控制癌症以及与不良血管生成有关或以不良血管生成为特征的疾病和失调的方法。具体方法包括单独施用选择性细胞因子抑制药物或与第二种活性成分联合施用。本发明还涉及减少或避免与化疗、放疗、激素治疗、生物治疗或免疫治疗相关的不良副作用的方法，其中包括施用选择性细胞因子抑制药物。本发明还公开了适用于本发明方法的药物组合物、单一单位剂型和试剂盒。
• Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
  申请人：——

  公开号：US20040091454A1

  公开（公告）日：2004-05-13

  Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本文公开了治疗、预防和/或控制黄斑变性的方法。具体的实施方案包括单独或与第二种活性剂和/或手术联合使用选择性细胞因子抑制药物或其药学上可接受的盐、溶液、水合物、立体异构体、凝胶体或原药。此外，还公开了适用于本发明方法的药物组合物、单一单位剂型和试剂盒。